cay10566 and Leukemia

cay10566 has been researched along with Leukemia* in 1 studies

Other Studies

1 other study(ies) available for cay10566 and Leukemia

Article	Year
Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors. Journal of medicinal chemistry, 2017, 05-25, Volume: 60, Issue:10 The dCTP pyrophosphatase 1 (dCTPase) is a nucleotide pool "housekeeping" enzyme responsible for the catabolism of canonical and noncanonical nucleoside triphosphates (dNTPs) and has been associated with cancer progression and cancer cell stemness. We have identified a series of piperazin-1-ylpyridazines as a new class of potent dCTPase inhibitors. Lead compounds increase dCTPase thermal and protease stability, display outstanding selectivity over related enzymes and synergize with a cytidine analogue against leukemic cells. This new class of dCTPase inhibitors lays the first stone toward the development of drug-like probes for the dCTPase enzyme. Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Humans; Leukemia; Molecular Docking Simulation; Piperazines; Pyridazines; Pyrophosphatases	2017

Article

Year

Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors.

Journal of medicinal chemistry, 2017, 05-25, Volume: 60, Issue:10

The dCTP pyrophosphatase 1 (dCTPase) is a nucleotide pool "housekeeping" enzyme responsible for the catabolism of canonical and noncanonical nucleoside triphosphates (dNTPs) and has been associated with cancer progression and cancer cell stemness. We have identified a series of piperazin-1-ylpyridazines as a new class of potent dCTPase inhibitors. Lead compounds increase dCTPase thermal and protease stability, display outstanding selectivity over related enzymes and synergize with a cytidine analogue against leukemic cells. This new class of dCTPase inhibitors lays the first stone toward the development of drug-like probes for the dCTPase enzyme.

Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Humans; Leukemia; Molecular Docking Simulation; Piperazines; Pyridazines; Pyrophosphatases

2017